Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2005

View Archived Issues

Preclinical data on EP4 receptor agonist ONO-4819

LXR - a novel therapeutic target for MS

Endocannabinoid improves clinical scores in MS mice

Imatinib mesylate - a novel strategy for pulmonary hypertension/News in Context

ISIS-3082 prevents postoperative ileus in vivo

A role for Src in lung cancer

Beneficial use of NO boosting agents for atherosclerosis

Callisto and Institute of Hepatitis Viral Research collaborate on biowarfare vaccines

Avidex licenses diabetes target from King's College London

Angiotech completes acquisition of Afmedica

FDA issues health alert over Menactra

MorphoSys begins new therapeutic antibody programs with Schering

Alpharma to study abuse-resistant extended-release opioid in phase II study

Enrollment makes good progress in phase IIb colorectal cancer study of CoFactor

Agensys and sanofi pasteur collaborate on colorectal and prostate cancer vaccines

M-Vax for melanoma launched in Switzerland

Blopress receives Japanese approval for chronic heart failure

Banyu obtains Japanese import approval for Propecia

Recent patents report new treatments for respiratory disorders

Purdue Research Foundation patents novel diagnostic agents

Recent patents describe novel antiinfective agents

Extension studies of asoprisnil to be amended

Cannabis-based medicine reduces central pain scores in MS patients

Good safety profile found for topical pimecrolimus in infants with atopic dermatitis

Snapshots on studies reported at the 2005 ASBMR and NAMS meetings

Eszopiclone shows efficacy in insomnia associated with menopause

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...